



## Aravax Appoints Dr Paul Laidler as VP Pharmaceutical Development

**1 May 2024, Melbourne, Australia:** Aravax, a clinical-stage biotechnology company developing next-generation immunotherapies which are safe, convenient, and precisely targeted, today announces the appointment of Dr Paul Laidler (BPharm, PhD) as Vice President, Pharmaceutical Development. Dr Laidler received both his Bachelor of Pharmacy and PhD degrees from King's College London.

Paul brings over 25 years' pharmaceutical development experience having held several roles within large Pharma companies including AstraZeneca and a number of pioneering biotechnology companies including PowderJect Technologies, Chiron Vaccines, PowderMed and Circassia Pharmaceuticals. Prior to joining the Aravax leadership team full time, Paul served as part-time consultant to the company for six years in the role Director of Product Development. Based in Oxford, UK he also serves as head of Aravax's UK operations.

Aravax raised US\$42m in a series B financing earlier this year, to accelerate the development of PVX108 as an oral immunotherapy for the treatment of peanut allergy. A Phase 2 clinical study is now underway in Australia and the USA, with readout is expected in H1 2026.

"We are thrilled that Paul has joined our team full time having worked closely with us during all stages of clinical development of PVX108. His skills and experience will be invaluable as Aravax scales up the manufacturing of PVX108 for late-stage clinical trials and commercial launch," **said Dr. Pascal Hickey, CEO of Aravax**, adding, "Being UK based, Paul is ideally located to maximise our partnerships with world-leading CDMO companies and our Europe-based collaborators outside of Australia."

**Dr Paul Laidler said**, "I am excited by the potential of PVX108 and our peptide immunotherapy approach. The company has made great advances with its groundbreaking treatment which has the potential to improve the lives of patients living with peanut allergy. PVX108 precisely targets the underlying cause of peanut allergy, bringing benefits in safety and convenience."



Dr Paul Laidler (BPharm, PhD), Vice President, Pharmaceutical Development, Aravax

**ENDS**

## **About Aravax**

Aravax is a clinical stage biotechnology company focused on revolutionising the treatment of food allergies with next-generation specific immunotherapies which are safe, effective and convenient. Aravax applies proprietary technology and know-how to design highly targeted pharmacotherapies, which reset the immune system to tolerate a specific allergen without evoking allergic reactions during treatment. The lead product, PVX108, is being developed for the treatment of peanut allergy.

Founded in 2015 based on technology from Alfred Health and Monash University, Aravax is a private company headquartered in Melbourne. Its investors include Brandon Capital, Tenmile, Novartis Venture Fund, Breakthrough Victoria, Uniseed, UniSuper and Agati Capital.

For more information visit: [www.aravax.com.au](http://www.aravax.com.au)